PharmaFox Therapeutics AG
Research - Möhlin, Aargau, Switzerland
PharmaFox Therapeutics AG Employees
PharmaFox Therapeutics AG Senior Management
PharmaFox Therapeutics AG Details
PharmaFox develops innovative compounds until clinical phase 1/2 for the pharmaceutical market. As soon as the early development phase is completed PharmaFox expects interest from Pharma companies. In this case it is foreseen that the assets will be sold. Investing in PharmaFox is a relatively low risk investment and can generate a high upside potential. The innovative pharma approach applied by the founders is already substantially de-risked. The companies lead compound is active in a high profile muscle disease (sarcopenia) making an early sale with an attractive deal probable. The ultimate goal of the investments is to create an optimal and realistic exit opportunity.
PharmaFox Therapeutics AG Technologies
Load Balancers
Nginx
Email Delivery
Sendgrid
Analytics and Tracking
Google Analytics
Other
Mobile Friendly
Hosting
Amazon AWS